

## INDEX

- <sup>13</sup>C-NMR, 301, 302  
<sup>14</sup>C-labelled creatine, 253  
<sup>1</sup>H-MRS, 122, 126, 133, 139, 152, 154, 156, 158, 168, 171, 172, 174, 176  
<sup>1</sup>H-NMR, 300, 301  
<sup>31</sup>P-MRS, 122, 123, 126, 129, 132, 134, 135, 138–142, 196  
5'-AMP-activated protein kinase (AMPK), 10, 251, 318  
Abluminal, 90, 94, 109  
Absorption, 102, 157, 261–265, 267, 268, 270, 303  
Absorptive functions, 108  
Acceptor control concept, 4  
Accessibility, 104, 105, 107  
Accumulation, 55, 77, 102, 110, 111, 126, 132, 152, 153, 157, 158, 160, 162, 169, 173, 197, 208, 245, 250–254, 256, 266, 270, 314, 316, 324  
Acetylaspartate, 122, 138, 139, 171, 176, 213  
Acidification, 129  
Action potential, 10, 161, 226  
Actomyosin, 51, 52, 54  
Additive effect, 195, 229  
Additives, 305  
Adenine nucleotides, 3, 5, 10, 27, 29, 33, 36, 39, 40, 49, 51, 52, 55  
Adenine nucleotide translocase, 5, 9, 29, 30, 41, 42, 46, 317  
Adenine nucleotide translocator, 27  
Adenosylhomocysteine, 150, 316  
Adenosylhomocysteine hydrolase deficiency, 316  
Adenosylmethionine, 150, 151, 161, 315  
Adenylate kinase, 29, 52, 53, 125, 126, 134, 135  
Adiposity, 305  
Adjunctive therapy, 183  
ADP, 3, 6, 8, 9, 17, 27, 29, 32–34, 36, 39–46, 49–52, 54, 55, 57, 85, 111, 124, 125, 131, 138–143, 150, 207, 299, 317, 322  
Adults, 75, 149, 152, 161, 184, 187, 194, 198, 219, 225, 246, 271, 281  
Adverse effect(s), 141, 178, 192, 283, 284, 286  
Adverse event, 271, 276, 284, 285, 288  
Affinity, 30, 31, 112, 126, 128, 143, 265, 312  
Affinity-purified antibody, 109  
AGAT, 18, 19, 25, 67–78, 85, 86, 92, 93, 149–151, 153, 154, 157–159, 162, 167–173, 178, 222, 310, 312, 314, 315, 320, 322–325  
AGAT activity, 150, 154, 170, 171  
AGAT-D, *see* AGAT deficiency  
AGAT deficiency, 73, 149, 151, 153, 154, 157, 162, 167–173, 179, 324  
Age, 24–227, 102, 133, 152–154, 157, 169–176, 178, 179, 185, 191, 208, 209, 212, 213, 215, 219, 220, 256, 312  
Aggregate, 109, 223  
AIDS, 221, 316  
Alcoholism, 221  
Alpers syndrome, 221  
ALS, *see* Amyotrophic lateral sclerosis  
Alzheimer's disease, 205, 215, 219  
Amacrine cell, 84  
Amidation, 292  
Amino acids, 93, 99, 101, 105–110, 151, 155, 169, 226, 253, 262, 267, 292, 294, 304  
Amino acid transporter, 74, 100, 101  
 $\gamma$ -Aminobutyric acid (GABA), 77, 100, 101, 104–107, 111, 113, 227, 313  
AMPK, 10, 251, 318  
Amygdala, 228  
Amylin, 111  
 $\beta$ -Amyloid, 220  
 $\beta$ -Amyloid-induced toxicity, 85  
Amyloid precursor protein, 220, 221, 323

- Amyotrophic lateral sclerosis, 9, 86, 89, 95, 184, 189, 205, 217–219, 270, 281, 284, 285, 325, 326  
 Anaerobic, 187, 188, 197, 222  
 Ancestor, 21, 23, 25  
 Ancestral protein, 17, 22  
 Angiogenesis, 75  
 Animal model, 9, 86, 95, 110, 120, 160, 212, 215, 218, 226–228, 252, 254, 276, 277, 319, 320, 322, 325  
 Anoxic damage, 113  
 Anti-arrhythmic, 317  
 Antibodies, 53, 99, 108–110, 150, 155  
 Antiepileptic drugs, 169  
 Anti-oxidant, 208, 210, 212, 220, 221, 227, 297, 305, 317  
 Anxiolytic, 161  
 Apical membrane, 102, 109  
 Apoptosis, 8, 9, 206, 208, 211, 218, 226  
 Apoptotic, 160, 206, 208, 211, 218, 226  
 Appetite, 305, 313  
*Aquifex aeolicus*, 103  
 (L-)arginine, 85, 89, 150, 151, 222, 310  
 (L-)arginine:glycine amidinotransferase, 85, 150, 151, 222, 310  
 Arginine:glycine amidinotransferase deficiency, *see* AGAT-deficiency  
 Arginine kinase, 17, 22, 29, 74, 140  
 Arginine restriction, 153, 160, 169, 170, 175, 178  
 Argininosuccinate lyase, 316  
 Argininosuccinate synthetase, 316  
 Arsenic, 284  
 Ascorbate, 284  
 Ascorbic acid, 227, 305, 316  
 Astrocyte(s), 68–71, 73–75, 83, 86, 91, 92, 109, 125, 158, 319  
 Astroglial-rich cultures, 100  
 Ataxia, 160, 185, 189, 196, 209, 211, 221  
 Athetosis, 160  
 Athlete(s), 6, 7, 207, 246, 247, 252, 266  
 ATP/ADP ratio, 8, 9, 52, 54, 124, 125  
 ATPase, 3, 8, 10, 23, 29, 40, 42, 45, 49, 51, 52, 54, 67, 77, 150, 159, 186, 247  
 ATP buffering, 3, 18, 23–25  
 ATP hydrolysis, 53, 54, 247  
 ATP synthase, 29, 34, 35, 54, 56  
 Atrophy, 86, 89, 93, 95, 155, 160, 184–187, 189, 194, 195, 209, 210, 212, 213, 223, 245, 250, 251, 311  
 Auditory brain stem, 108, 315  
 Autism, 152  
 Autistic, 85, 99, 152, 169, 173  
 Autistic like behaviour, 8, 149, 169, 172  
 Autoimmune, 184  
 Autophagy, 186  
 Autosomal dominant, 185, 208  
 Autosomal recessive, 149, 152, 154, 170, 173, 185, 223, 316  
 Axon(s), 67, 74, 92, 184, 226  
 Axonal elongation, 92  
 Axonal growth, 159  
 Axonal networks, 159  
 Bacteria, 100, 263, 265  
 Bacterial leucine transporter (LeuT<sub>Ad</sub>), 103  
 Basal, 21–23, 57, 75, 126, 136, 139, 153, 187, 251, 253  
 Basal ganglia, 153, 210, 212  
 Basolateral, 102, 262, 265  
 Baycol (cerivastatin), 275  
 BBB, *see* Blood-brain barrier  
 B-CK, 125, 129, 134–140, 142, 143, 312, 313, 315  
 Becker's muscular dystrophy, 183, 185, 190, 191, 314  
 Benefits 2, 10, 11, 183, 185–188, 198, 213, 247, 256, 275, 305, 311, 316, 321, 325, 326  
 Benzoate, 153, 169, 175, 178  
 Betaine, 100, 317  
 Binding motif, 108  
 Binding sites, 41, 43, 101, 103–107  
 Bioavailability, 214, 228, 263–265, 270, 305  
 Biochemical conversion, 129  
 Biochemical hallmarks, 149, 154, 156  
 Bioenergetics, 1, 11, 28, 143, 218, 221  
 Bioequivalence, 263–265  
 Biosynthesis, 7, 8, 17–19, 25, 83, 85, 86, 91–94, 99, 124, 149–155, 157–159, 161, 167, 222, 309, 310, 315, 320, 325  
 Bipolar cell, 84  
 Blood, 68, 71, 74–76, 78, 85–88, 92, 93, 110, 124, 158, 167, 169, 171–174, 176, 178, 192, 214, 223–227, 262, 265, 267–270, 276, 277, 279–281, 283, 284, 299, 320, 324  
 Blood-brain, 2, 72  
 Blood-brain barrier, 68–72, 74–76, 83–90, 93–95, 109, 126, 158, 168, 225, 266, 313, 321  
 Blood pressure, 280, 283, 318  
 Blood-retina(l) barrier, 2, 71, 83–85, 310, 321  
 BMD, *see* Becker's muscular dystrophy  
 Body building, 318, 320  
 Body fluid, 120, 149, 152, 154, 169, 172, 299  
 Body function, 2  
 Body temperature, 6, 121, 279, 280  
 Body weight, 126, 190, 213, 222, 250, 281, 316, 326

- Bone repair, 314  
Brain, 2, 7–10, 28, 40, 67  
Brain atrophy, 155, 160, 212, 213  
Brain CK (B-CK), 135, 136  
Brain development, 2, 7, 75, 78, 159, 160, 172, 173  
Brain function, 7, 85, 99, 113, 136, 162, 323, 325  
Brain stem, 108, 188, 205, 315  
Breast-fed, 170, 171, 173  
Breed, 6  
Brush-border membranes, 102  
Burst activity, 132, 135  
By-product(s), 292, 303, 304
- C<sub>2</sub>C<sub>12</sub> muscle cells, 112  
Cachexia, 316  
Caco-2 monolayer, 262  
Caffeine, 247, 248  
CAG repeat, 209  
Calcium homeostasis, 8, 9, 186, 225  
Calcium overload, 8, 9  
Calcium pump, 8, 9  
Calcium sequestration, 8  
Capillaries, 75, 90, 91, 93, 109  
Capillary endothelial cells, 68–70, 84, 86, 90, 158, 313  
Capsule(s), 264  
Carbohydrate(s), 29, 104, 198, 247, 251, 253, 254, 261, 265, 267, 270, 271, 305  
Carboxyl group, 101, 106, 303  
Cardiac cell, 27, 28, 45, 48, 50–54  
Cardiac failure, 185  
Cardiac muscle, 28, 54, 136, 140, 265, 276, 314  
Cardiolipin, 27, 30–32, 40, 43, 55  
Cardiomyocyte, 45, 46, 52, 53  
Cardio-protective, 188  
Carnitine, 101, 305  
Carnitine creatinate, 305  
Carnitine palmitoyl transferase deficiency, 185  
Carrier(s), 5, 20, 29, 31, 32, 54, 88, 99, 100, 112, 150, 153, 155, 156  
Carry-over effect, 189  
Case study (studies), 157, 221, 276, 281, 283  
Caspase, 206, 211, 216, 224  
Caspase cell-death pathways, 9, 224  
Catecholamine(s), 267  
CCDSs, *see* Cerebral creatine deficiency syndrome  
CDSs, *see* Cerebral creatine deficiency syndrome  
Cell bodies, 92  
Cell death, 9, 44, 206, 208, 211, 220, 224, 226  
Cell surface, 112, 253  
Central nervous system, 67–69, 71–78, 152, 186, 217, 221, 225, 313, 322, 323  
Cerebellum, 69, 70, 108, 221, 313  
Cerebral creatine, 85, 100, 149, 152, 154–156, 158, 160  
Cerebral creatine deficiency syndrome, 149–152, 156, 158, 161, 162, 310–312, 318, 319, 321–324  
Cerebral ischemia, 9, 224  
Cerebrospinal fluid, 69, 70, 76  
Cerivastatin, 275, 276  
Channel(s), 9, 29, 30, 46, 51–53, 104, 108, 112, 161, 186, 210, 226, 321  
Channelopathies, 184, 185  
Charcot-Marie-Tooth, 183, 184, 187, 190, 193, 194, 199  
Chemical analysis, 129, 298  
Chemical synthesis, 2, 291–293  
Chemistry, 291, 292  
Children, 149, 152, 156, 161, 167, 191, 194, 221, 225, 326  
Cho, *see* Choline compounds  
Choanocyte, 17, 24  
Cholesterol, 275, 276, 283  
Choline, 89, 101, 122, 138, 176, 316  
Choline compounds, 121  
Choline transporter, 101, 108  
Chondrocyte, 194  
Chorea, 160  
Chorioretinal, 86, 93, 223  
Choroid plexus, 69–762, 75, 76, 78  
Chromosome, 100, 152, 154, 175, 222  
Chronic progressive external ophthalmoplegia, 185  
Citrate, 246, 304, 305  
Citrulline, 101  
CK, 1–11, 17–19, 21, 23–25, 27–30, 33, 34, 36, 37, 41, 42, 46, 51, 52–58, 67, 71, 73, 74, 77, 91–94, 120, 123–126, 128–143, 150, 151, 192, 220, 254, 278, 310–327  
CK-B, 91, 92  
CK/PCr circuit, 4  
CK phosphotransfer network, 2, 310  
CL<sub>BBB</sub>, 87, 88  
CL<sub>BBB</sub>, 87  
Clearance, 87, 88, 195, 261, 264–268, 270, 271, 279, 281, 282  
Clinical features, 153  
Clinical study (studies), 153  
Clinical symptoms, 2, 8, 151, 156, 159, 169, 170, 172, 178, 185, 213, 215, 221, 222

- Clinical trial(s), 183, 189, 190, 198, 199,  
213–217, 219–221, 228, 229, 261, 276, 277,  
283, 311
- CMT, *see* Charcot-Marie-Tooth
- CNS, *see* Central nervous system
- Cockcroft-Gault equation, 279
- Coenzyme Q<sub>10</sub>, 187, 196, 212, 216, 219, 221, 222
- Cognitive, 136, 169, 195, 214
- Cognitive function, 178
- Colorectal cancer, 316
- Combination therapy, 187, 216, 311, 314, 317
- Compartmentalization of metabolites, 121
- Compartment pressure, 276
- Compartment syndrome, 246, 278
- Compensatory events, 6
- Competitive inhibitor, 101, 158, 160, 169
- Concentration, 6, 9, 19, 30, 31, 33, 34, 36, 37,  
39, 40, 45, 46, 50–57, 71, 73, 85, 87, 88, 93,  
99, 102, 104, 110–112, 121, 123, 127, 128,  
130–134, 137, 139, 140, 142, 150, 156–160,  
167–169, 171, 172, 174, 176, 178, 188, 192,  
198, 208, 210, 213, 214, 219, 220, 224, 228,  
245, 252, 296–300, 312, 313, 316, 320,  
321, 325
- Concentration gradient, 19, 39, 71, 88, 111, 320
- Concentration-time curve, 87, 264
- Concentration-time profile, 262, 264
- Congenital, 111, 173, 184, 225
- Conserved, 17, 103, 104, 107, 110, 175, 209
- Constipation, 285
- Contractions, 3, 4, 29, 52, 54–56, 58, 99, 112,  
191, 193, 196, 198, 247–249, 253, 256, 277,  
278, 311
- Coprophagia, 128, 132
- Corpus callosum, 70
- Cortex, 91, 102, 108, 161, 210, 214, 220, 223,  
225, 226, 313
- Cortical function, 173
- Corticosteroid(s), 184–187, 190–192, 194, 195,  
197, 198
- Co-transport, 100, 112
- CPEO, 185, 196
- Cr deficiency, 2, 7, 68, 73, 125, 142, 167, 170,  
173, 223, 318, 322–325
- CreaT, 18–20, 25, 207
- Creatine, 1, 4, 6, 9, 17, 18, 23, 32, 33, 67, 75, 83,  
85–90, 92–95, 99–102, 104–106, 108–113,  
119–122, 124–126, 132, 137, 138, 143, 144,  
149–162, 167, 171, 184, 186–198, 207, 208,  
212–225, 227, 228, 245–256, 261–271,  
275–286, 291–305, 309, 327
- Creatine analog, 99, 155
- Creatine:creatinine ratio, 106
- Creatine deficiency, 100, 152, 154, 157, 159, 162
- Creatine deficiency syndromes, 83, 85, 93, 119,  
149, 162, 310, 312, 323
- Creatine depletion, 111, 159, 162, 254
- Creatine disposition, 261, 263, 266, 269
- Creatine hydroxycitrate, 305
- Creatine kinase, 1–11, 17–19, 21, 23–25, 27–34,  
36, 37, 41, 42, 46, 67, 71, 73, 74, 77, 91–94,  
119, 120, 123–126, 129–143, 150, 151, 191,  
192, 198, 207, 208, 212, 220, 247, 254, 269,  
277, 278, 299, 309–324, 327
- Creatine loading, 245–247, 250, 252, 254, 256
- Creatine monohydrate 150, 152–156, 183, 186,  
208, 216, 219, 221, 222, 245, 246, 255, 256,  
262, 268, 292, 295, 297, 301–305
- Creatine/phosphocreatine shuttle, 83, 85, 92, 93
- Creatine production, 264, 284, 295
- Creatine replacement, 167
- Creatine supplementation, 6, 7, 21–225, 83, 86,  
93, 95, 110, 113, 122, 152, 154, 157, 168,  
171, 183, 185–189, 191–195, 198, 205–208,  
212, 214–216, 228, 245–252, 254–256, 261,  
264, 266, 268–270, 275–284, 286
- Creatine transport activity, 110, 253
- Creatine transport(er), 83, 85, 86, 88, 93, 94,  
99–102, 106, 109, 110, 112, 149–152,  
154–160, 162, 207, 213, 215, 222, 253–256,  
262, 266–270, 282
- Creatine transporter deficiency, 149, 152
- Creatine uptake, 87–89, 99–101, 108, 110–112,  
150, 151, 154–156, 187, 198, 248, 253, 254,  
266, 267, 269, 271, 276
- Creatinine, 1, 6, 18, 19, 89, 99–101, 106, 125,  
149, 152, 154–157, 162, 173–176, 178, 192,  
194, 195, 207, 222, 263, 264, 267, 271,  
279–282, 284, 291, 292, 296, 297, 299, 300,  
303–305, 324
- Creatinuria, 270
- Crn, *see* Creatinine
- Cross-over design, 189, 191, 192, 196
- Cross-react, 109, 255
- Cr pool, 8, 18, 19, 68, 73, 74, 123, 168, 172,  
173, 178
- Cr-stimulated respiration, 5, 33, 317
- Cr supplementation, 2, 3, 6–11, 68, 69, 73, 127,  
128, 132, 167–169, 172, 311, 313, 314–316,  
318, 320, 321, 325, 326
- Cr synthesis, 2, 33, 57, 67, 69, 74, 76, 77, 172,  
173, 315
- CRT, 2, 8, 18, 68, 83, 85, 86, 88–90, 93–95, 99,  
310, 312–315, 317, 318, 320–323, 325
- Crystal structure, 103
- CSF, *see* Cerebrospinal fluid

- c-Src tyrosine kinase, 112  
 CT1, 67–78, 167, 172, 310  
 Cyanamide, 284, 292–294, 304  
 Cyanide, 294  
 Cybrid(s), 188, 199  
 Cycling, 52, 251, 252, 279, 280, 317  
 Cyclocreatine, 141  
 Cyclosporine, 281, 282  
 Cyclosporine A, 112  
 Cysteamine, 316  
 Cystine, 316  
 Cystinosis, 316  
 CytCK, 21, 22  
 Cytochrome c, 46, 159, 206, 218, 224  
 Cytochrome oxidase, 212, 220  
 Cytoplasmic-flagellar genes, 17, 21  
 Cytotoxic, 284  
 Cytotoxicity, 284
- Danio rerio*, 101  
 Death, 9, 44, 160, 184, 205, 206, 208, 209, 211, 212, 217–221, 223–226  
 Deflazacort, 185, 191  
 Degeneration, 86, 93, 209, 210, 216, 217, 221, 223, 315  
 Dehydration, 277, 278, 280, 286  
 Deletion, 6, 106, 107, 140, 143, 153, 156, 184, 196  
 Dementia, 208, 219  
 Dendrite(s), 67, 74, 92, 159  
*De novo* mutation, 156  
 Dermatomyositis, 184, 195  
 Deterioration, 85, 191, 195, 209, 216  
 Development, 2–4, 7, 8, 10, 52, 67–69, 71–75, 77, 78, 83, 85, 95, 99, 109, 125, 135, 144, 150, 152, 154, 159, 160, 162, 169, 172, 173, 176, 178, 188, 198, 199, 275, 292, 304, 310, 313, 316, 319, 323–325  
 Diabetes, 184, 189, 252, 254  
 Diabetic, 184, 187  
 Diabetic neuropathy, 187, 198  
 Diagnostic hint, 152  
 Diagnostic marker, 157, 172  
 Diagnostic options, 152  
 Dialysis, 194, 219  
 Diaphragm, 195, 316  
 Diarrhea, 283, 285  
 Diarrhoea, 172  
 Dicyandiamide, 284, 300, 303, 304  
 Diet, 18, 67–69, 143, 153, 169–171, 176, 207, 212–214, 218, 221, 227, 262  
 Dietary restriction(s), 8, 153  
 Dietary supplement, 11, 189, 284, 291, 305  
 Dietary supplementation, 8, 86, 110, 172, 327  
 Dietary Supplements Health and Education Act, 305  
 Differential diagnosis, 149, 156  
 Differentiation, 313  
 Dihydrotriazine(s), 284, 300, 303, 304  
 Dimer, 5, 21, 30, 31, 40, 43, 134, 212  
 Dimethyl sulphate, 304  
 Disease progression, 161, 214–216, 219  
 Disease registries, 162, 323, 324  
 Diuretics, 278  
 Divergence, 17, 21, 23, 25  
 DMD, *see* Duchenne muscular dystrophy  
 DNA, 100, 106, 158, 170, 175, 188, 196, 206, 210, 218, 220, 221, 226, 284, 315, 323, 324  
 DNA microarray, 323  
 DNA oxidation, 210  
 DNA repair, 206  
 DNFB, 3  
 Domain, 6, 21, 22, 31, 102–104, 107, 108  
 Dopamine, 100, 107, 215, 216  
 Dorsi-flexion, 190, 192, 193, 196  
 Dosage, 11, 158, 167–169, 172, 173, 175, 178, 246, 250, 265, 270, 276, 278, 283, 311, 319, 325, 326  
 Dosage form, 264, 265, 270, 283  
 Dosage (recommended), 246  
 Doses per day, 169, 172, 175  
 Dosing, 214, 215, 216, 262, 267, 270, 271, 279  
 Double knock-out animals, 5, 124, 136  
 Down-regulates, 110  
 Down-regulation, 109, 112, 213, 214, 216  
 Down syndrome, 159  
 Dpd, *see* Doses per day  
 Dried blood spots, 172–174, 324  
 Duchenne muscular dystrophy, 183–186, 190, 191, 194, 195, 197, 314  
 Dynamic compartmentation, 39, 40, 43–55, 57  
 Dysmorphic features, 155  
 Dystonia, 212  
 Dystrophin, 185  
 Dystrophinopathy, 185, 191, 192, 198  
 Dystrophy, 8, 111, 183–185, 189–195, 197, 270, 314
- E. coli*, 19, 21, 319  
 Ear, 5, 315  
 Early treatment, 153, 154, 171, 173, 178, 179  
 ECL4, 103, 107  
 Edema, 223, 225, 285  
 EEG, 152, 154, 173

- Elderly, 161, 261, 269, 271, 311  
 Electric field stimulation, 112  
 Electric ray, 20, 101, 108  
 Electrochemical gradients, 100  
 Electrogenicity, 102  
 Electrolysis, 112, 253  
 Electron microscopy, 91, 109  
 Electron transport, 210  
 Electron transport chain, 185, 186, 210, 211, 215, 216  
 Elimination, 268  
 Elimination rate, 263  
 Embryo, 68, 69, 71, 75, 172  
 Embryogenesis, 73, 159  
 Embryonic development, 68, 69, 71, 72, 75  
 Embryonic stem cell(s), 120, 125, 135  
 EMG, 197  
 Endocytosis, 111, 112  
 Endogenous (bio)synthesis, 67, 69, 74, 75, 77, 78, 207  
 Endosome, 111  
 Endothelial cell, 68–70, 72, 75, 76, 84, 86, 88, 90, 95, 158, 313, 317  
 Endotoxin, 316  
 Endurance, 183, 186, 188, 192, 247, 248, 318  
 Endurance capacity, 247  
 Endurance performance, 196  
 Energy buffer, 9, 207, 275  
 Energy failure, 159, 223  
 Energy homeostasis, 11, 25, 71, 83, 92–94, 159, 205, 207, 212  
 Energy supplying pathways, 120  
 Energy turnover, 2, 247  
 Enterocyte(s), 102, 109, 262, 264  
 Environmental stress, 280  
 Enzymatic determination, 299  
 Enzyme, 4, 5, 7, 9, 11, 17, 19, 25, 27, 34, 36, 41, 55, 67, 68, 91, 92, 119, 120, 124–126, 129, 134, 135, 140, 143, 150, 153, 154, 157, 161, 169, 171, 175, 206, 216, 217, 220–222, 299, 309, 310, 314, 319, 320  
 Ependymal, 69–71, 75, 76, 78  
 Ephedrine, 278  
 Epilepsy, 8, 85, 92, 92, 94, 99, 149, 152, 153, 156, 162, 173, 205, 221, 225–228  
 Epileptogenic, 77, 160, 169, 173, 228  
 Epithelia, 69–71, 78, 264  
 Ergogenic, 1, 2, 7, 11, 207, 245–247, 251, 252, 305, 311, 318, 325  
 EST sequences, 19  
 Etiology, 106, 149, 219, 225  
 European parliament, 305  
 Evolution, 2, 5, 17, 18, 23  
 Evolutionary, 25, 310, 318  
 Excitatory neurons, 92  
 Excitotoxic, 160, 210  
 Excitotoxicity, 85, 206, 208, 210, 211, 214, 221, 223  
 Excretion, 152, 157, 190–192, 207, 222, 253, 261, 268, 269, 279, 314  
 Exercise, 7, 183, 185, 188, 192–198, 222, 245, 247, 248, 250–254, 256, 267, 269, 271, 275, 277–281, 283, 305, 311  
 Exercise challenge, 277, 278  
 Exercise intolerance, 185  
 Exocytosis, 111  
 Exocytotic, 10, 161  
 Exocytotic release of Cr, 10  
 Exogenous, 33, 45, 46, 48–52, 85, 88, 261, 270, 276, 314  
 Expression, 10, 24, 67–78, 88–92, 95, 100, 101, 103, 108, 111, 112, 119, 120, 125, 126, 129, 140, 142, 150, 172, 183, 217, 245, 250–253, 255, 270, 310, 313–315, 317–320, 322, 323  
 Expressive speech, 149  
 External gate, 103  
 Extracellular creatine, 111, 112, 150, 253, 320, 321  
 Extracellular loop, 102–104  
 Extra-pyramidal, 85, 222  
 Extraparallel movement disorder, 92, 152, 153, 160, 173  
 Facilitated diffusion, 125  
 Fascioscapulothoracic, 190  
 Fast-twitch fiber, 6, 254–256  
 Fat-free, 183, 190, 192, 193, 196, 249, 250, 291  
 Fatigue, 186, 191, 251, 275, 276, 279  
 Fatty acid oxidation defect, 183, 188  
 Feces, 263  
 Feedback mechanism, 157  
 Female, 22, 151, 155–157, 269, 324  
 Fertility, 126  
 Fertilization, 23  
 Fibroblast(s), 106, 154–156, 158, 314  
 Filtration, 267, 270, 279  
 Fish, 6, 101, 150, 207, 245, 264  
 Flagellar CK gene families, 17, 18, 21, 22  
 Flesh, 291  
 FlgCK, 18, 21–23, 25  
 Flux, 5, 113, 133, 135, 137, 139, 142, 169, 188, 197, 247, 262  
 Flux rates, 123  
 Food, 124, 255, 261, 265, 267, 271, 275, 305, 323  
 Food additive, 305

- Food supplement, 305  
 Formaldehyde, 284, 288, 294  
 Formate, 284  
 Formulation, 54, 178, 213, 246, 264, 265, 291, 296, 297, 300, 303–305  
 Fragile X syndrome, 155, 159  
 Frameshift, 106, 153, 175  
 Free radical, 206, 210, 211, 216, 226, 227, 314, 316  
 Frequency, 52, 106, 121, 127, 128, 155, 179, 194, 197, 218, 224, 227, 228, 268, 301  
 Fructose, 142, 265, 267, 283  
 Fructose-1-phosphate, 142  
 Fruit juice, 265, 267, 283  
 Fumarate, 304  
 Function, 2, 3, 5–11, 17, 27–29, 37, 39, 43, 51, 52, 54, 58, 67, 71, 73, 78, 83, 85, 88, 89, 91, 93–95, 99, 102, 103, 106–108, 113, 120, 128, 134–136, 137, 140, 143, 151, 152, 156, 158, 162, 173, 178, 183–186, 189–198, 206, 208, 209, 211, 216, 218, 222, 224, 246, 261, 264, 266, 269, 271, 275, 279, 281–283, 309–315, 318–325, 327  
 Functional genomics, 321–323  
 Functional task, 191, 193, 196  
 Fungi, 100
- G8 cultured skeletal myoblasts, 111  
 GAA, 73, 77, 78, 125, 126, 128, 149, 150, 152–154, 157–160, 162, 169–174, 176, 178, 179  
 GABA, 77, 100, 101, 104–107, 111, 113, 227, 313  
 GABA<sub>A</sub> receptors, 10, 77, 160, 161  
 Gait, 176, 184, 215  
 Galenical form, 291  
 Gametes, 23  
 Gametogenesis, 24  
 GAMT, *see* Guanidinoacetate methyltransferase  
 GAMT activity, 69, 150, 152, 157, 175  
 GAMT-D, *see* Guanidinoacetate methyltransferase deficiency  
 GAMT deficiency, *see* Guanidinoacetate methyltransferase deficiency  
 GAMT expression, 68, 75, 77, 92, 126  
 Ganglion cell, 84, 91  
 Gastric emptying, 265  
 Gastrocnemius, 110–112, 195, 254  
 Gastrointestinal discomfort, 275, 286  
 Gastrointestinal distress, 283  
 Gastrointestinal tract, 262, 264, 270, 275, 305  
 Gender, 256
- Gene duplication, 21, 23  
 Gene targeting, 125  
 Genetic manipulation, 94, 140, 143, 215  
 Genetic polymorphism, 318  
 Genomic database, 19, 20  
 Genotype-phenotype, 153, 156  
 Geriatric, 269  
 GFP, *see* Green fluorescent protein  
 GFR, *see* Glomerular filtration rate  
 Glia, 83, 85, 91–94  
 Glial mitochondria, 92  
 Globus pallidus, 108, 152, 159  
 Glomerular filtration rate, 267, 279  
 Glomerulonephritis, 283  
 Glomerulosclerosis, 281, 283  
 Glucocorticoid, 112  
 Glucose, 83, 85, 93, 123, 173, 188, 210, 226, 227, 251–253, 262, 267, 271, 280, 317  
 Glucose tolerance, 251, 252  
 Glucose transporter, 94, 251  
 Glucose transporter 1, 85  
 Glucose transporter 4, 245, 318  
 GLUT1, *see* Glucose transporter 1  
 GLUT4, *see* Glucose transporter 4  
 Glutamate, 34, 122, 138, 139, 159, 208, 212, 214, 218, 219, 226, 227  
 Glutamate excitotoxicity, 85  
*Glycera dibranchiata*, 19  
 Glycine, 18, 67, 68, 89, 92, 93, 108, 150, 151, 155, 169, 170, 207, 315  
 Glycocyanine, 17  
 Glycogen, 123, 245–247, 251, 252, 256  
 Glycogenolysis, 18, 185, 188, 197  
 Glycogen storage disease, 185, 187, 197  
 Glycolysis, 92, 128, 188, 208  
 Glycolytic fast-twitch fibers, 6  
 Glycosylation, 102, 103, 109  
 Gout, 188  
 GPA, 110, 111, 129, 254, 255  
 Granule cell layers, 108  
 Green fluorescent protein, 94, 113  
 Grey matter, 168  
 Growth cone, 67, 74, 92  
 Growth factor, 111, 113, 245  
 Growth hormone, 111, 112  
 Growth retardation, 155, 194  
 GSD VII (phosphofructokinase deficiency/Tarui's disease), 185  
 Guanidinoacetate, 19, 89, 99, 101, 124, 126, 151, 169, 169, 170, 174, 175, 313, 316, 320, 324, 325  
 Guanidinoacetate lowering, 167, 169

- Guanidinoacetate methyltransferase, 2, 7, 18, 19, 25, 67–78, 85, 86, 91, 92, 94, 119, 120, 122, 124–128, 132, 136, 139, 143, 149–154, 157–162, 172, 175, 222, 310, 312, 319, 322–325  
 Guanidinoacetate methyltransferase deficiency, 73, 77, 86, 92, 126, 143, 149, 151–154, 157–162, 167–170, 173–176, 178, 179, 310, 324, 325  
 Guanidinoacetate N-methyltransferase, 85, 94  
 Guanidinobutyrate, 89, 101, 160  
 Guanidino compound, 6, 160, 169, 174, 175, 207, 245, 292  
 Guanidino group, 101  
 Guanidino kinase, 17  
 ( $\beta$ -) Guanidinopropionate, 89, 101, 110, 129, 160, 255  
 Guanidinosuccinate, 160  
 Guanylation, 292, 294, 295  
 Guanylation reagents, 292  
 Gyrate atrophy, 89, 93, 95, 223  
 Gyrate atrophy of the choroid and retina, 86, 95
- Haemagglutinin-tagged, 103  
 Hair bundle cells, 5  
 Half-life, 112, 267, 268  
 Hand-grip strength, 190, 192  
 Health, 1–3, 10, 11, 85, 183, 224, 283, 309, 318–321, 326, 327  
 Health-beneficial effect, 325, 326  
 Health benefit(s), 2, 321, 325, 326  
 Hearing loss, 315  
 Heart, 4, 11, 28, 33, 34, 38, 40, 44, 46, 51–53, 55, 58, 108, 110, 119, 120, 125, 127–129, 136, 138–141, 157, 186, 188, 189, 276, 279, 280, 314, 316, 318  
 Heart failure, 111, 186, 188, 270, 314  
 Heat stress, 279, 280  
 Heat tolerance, 277  
 Heavy metal, 303  
 HEK293 cells, 102, 103, 107, 109  
 Helix, 103, 105, 107  
 Hemizygous mutation, 151, 154, 156  
 Hemodynamic response, 136  
 Hepatic, 71, 275, 283  
 Herbivores, 19  
 High-dose ornithine, 169, 170, 178  
 High-energy phosphate, 5, 54, 67, 99, 108, 124, 125, 136, 139, 142, 150, 159, 206–208, 211, 216, 227, 228, 310, 315, 316, 319, 323, 325  
 High-energy phosphoryl transfer, 29, 119, 129, 132
- High performance liquid chromatography (HPLC), 134, 227, 294, 295, 300, 303  
 Hippocampus, 70, 72, 85, 108, 135, 225, 315  
 Homeostasis, 8, 9, 11, 25, 67, 71, 83, 92–94, 159, 186, 205–207, 212, 224, 225, 315  
 Homologous transporters, 100  
 Homologue, 17, 99, 100, 103, 104, 110, 310  
 Horizontal cell, 84  
 Hormone, 108, 111, 112, 150  
 HPLC, *see* High performance liquid chromatography (HPLC)  
 Huntingtin, 209, 211, 213  
 Huntington's disease, 9, 86, 95, 205, 208–219, 228, 252, 266, 313  
 Hydrogen peroxide, 208, 284  
 Hydroxycitrate, 305  
 Hydroxykynurenine, 313  
 Hyperactive impulsive attention deficit, 155  
 Hyperammonemic, 89  
 Hyperargininemic, 313  
 Hypercreatinemia, 270  
 Hyperglycemic, 252, 317  
 Hyper-hydrating, 279  
 Hyperornithinemia, 86, 93, 223  
 Hyperosmotic stress, 112  
 Hypertonic, 10, 317  
 Hypertonic stress, 10, 317  
 Hypertrophy, 111, 245, 250, 251, 256  
 Hyperuricemia, 188  
 Hypocreatinemia, 270  
 Hypoglycemia, 92  
 Hypohydration, 279  
 Hypo-osmotic swelling, 10  
 Hypotaurocyamine, 17  
 Hypotonia, 126, 152, 154, 155, 172, 316  
 Hypoxia, 92, 141, 223–225, 227  
 Hypoxic damage, 85
- iBRB, *see* Inner blood-retinal barrier  
 ICEU, *see* Intracellular energetic unit  
 IGF-1, 112, 250, 267  
 Ileum, 109, 262  
 Immobilization, 251, 311  
 Immunoelectron microscopy, 92  
 Immunohistochemical localization, 91  
 Immunoprecipitation, 53, 112  
 Immunosuppressive therapy, 195  
 Impurities, 283, 284, 291, 300, 303, 304  
 Inborn error, 149, 150, 162  
 Inborn error of metabolism, 149, 150, 167, 185, 222, 324  
 Inclusion body myositis, 184, 195, 198, 199



- Index girls, 156  
 Industrial production, 292  
 Infarct, 224, 276  
 Inflammation, 186, 225, 281  
 Inflammatory myopathy, 111, 183, 190, 195  
 Infrared, 298, 303  
 Inherited, 2, 7, 173, 179, 183, 184, 198, 208, 217, 226, 310, 312, 313  
 Injury, 8, 9, 206, 223–226, 281, 326  
 Inner blood-retinal barrier, 83–86, 88–90, 93–95  
 Inner ear, 5, 315  
 Inorganic phosphate, 17, 18, 123, 139, 210, 223  
*In situ* hybridization, 90, 108  
 Insulin, 111, 245, 246, 251–254, 261, 267, 271, 276, 317  
 Insulin-like growth factor, 111, 245  
 Insulin sensitivity, 251, 252  
 Intellectual deficit, 153, 154  
 Intelligence, 313  
 Intermembrane space, 30–32, 39, 40, 43, 48, 50, 54, 150  
 Internal gate, 103  
 Interstitial nephritis, 281  
 Intestinal absorption, 262  
 Intestinal enterocytes, 102, 109  
 Intestine, 6, 108, 261, 262, 264, 265, 283  
 Intracellular creatine levels, 207  
 Intracellular diffusion, 27, 45, 51  
 Intracellular energetic unit, 29, 50, 54  
 Intraperitoneal, 225  
 Intravenous, 87, 223, 252, 263  
 Invertebrate, 18–21, 23, 25, 310  
 Ion gradient, 67, 223  
 Ionic gradients, 86  
 IR spectroscopy, 300–302  
 Ischemic, 113, 129, 139, 141, 197, 222, 224  
 Ischemic stroke, 205, 223, 224  
 Isoenzymes, 2, 5, 6, 28–30, 33, 55, 58, 119, 120, 125, 129, 133–135, 140, 142, 220, 309, 310, 312, 314, 315, 319  
 Isoform, 4, 18, 21, 23–25, 28, 93, 112, 125, 129, 134, 136, 142  
 Isoproterenol, 111  
  
 Jejunum, 262  
  
 Kainate, 226–228  
 Kearns Sayre syndrome, 195, 196, 221, 222  
 Keratinocyte, 109, 314  
 Ketogenic diet, 227  
  
 Kidney, 67–69, 71, 86, 102, 108, 113, 150, 158, 207, 246, 261, 265, 267, 268, 270, 275, 279, 281  
 Kinetic constant, 36, 37, 40, 42, 43  
 Kinetics, 19, 27, 33, 34, 37, 43–45, 52, 54, 55, 100, 126, 129, 262–265, 268–270, 282  
 Kinetic scheme, 34, 37, 40, 44  
 $K_m$ , 19–21, 34, 45, 48–52, 88, 89, 102, 104, 110, 262, 266, 268, 269, 271, 277, 278  
 Knock-in, 319  
 Knock-in mice, 113  
 Knock-out, 113  
 Knock-out mice, 5, 6, 44, 71, 120, 133, 135, 143, 157, 162, 315, 325  
 $K_{p,app}(t)$ , 87, 88  
 Kreas, 6  
 KSS, *see* Kearns Sayre syndrome  
  
 L6 myoblasts, 112, 251  
 Lactate, 3, 83, 85, 93, 123, 196, 210, 212, 225–227, 280, 299  
 Lactate dehydrogenase, 34, 277, 278, 299  
 Language delay, 8, 94, 99, 100, 149, 155  
 LCHAD deficiency, 188, 189  
 Lean body mass, 267  
 Leber's optic neuropathy, 210  
 Lectin, 102  
 Legal status, 291  
 Leigh's disease, 185  
 Leigh syndrome, 221, 222  
 Liebig's Fleischextrakt, 291  
 Liebig's meat extract, 6  
 Life expectancy, 161  
 Limb girdle muscular dystrophy, 184, 191  
 Lipid bilayer, 103  
 Lipid peroxidation, 208, 210, 213  
 Lipids, 121, 226, 283, 317  
 Lipid transfer, 30, 317  
 Lipoic acid, 187, 189, 193, 196, 198, 212  
 Liquid chromatography, 174, 284, 298, 300  
 Liver, 9, 23, 67–69, 72, 86, 119, 120, 124, 129, 140–142, 150, 152, 158, 173, 192, 207, 218, 279, 283, 317, 319, 320  
 Liver failure, 313  
 Livestock production, 318  
 Loading dose, 271, 282  
 Loading phase, 246, 271, 282, 320  
 Localization, 30, 32, 51, 53, 90, 91, 93, 99, 108, 109, 134, 140, 211, 225, 310, 318  
 Lombricine, 17  
 Long-term, 74, 126, 152, 167, 168, 187, 188, 196–199, 223, 224, 228, 246–248, 275

- Long-term safety, 246, 311  
 Loop, 102–104, 107  
 Low-dose ornithine, 169, 178  
 Lozenge, 264  
 Luminal, 75, 90, 94, 109  
 Lymphoblast(s), 154, 158, 170, 171, 175  
 Lymphocyte, 170, 171
- Macrophage(s), 100  
 Magnet, 121  
 Magnetization transfer, 123, 129, 133  
 Maintenance dose(s), 246, 271, 282  
 Maintenance phase, 282, 320  
 Maleate, 304  
 Malonate, 212  
 Mammalian, 9, 19, 67–69, 71, 73–76, 101–105, 107, 108, 112, 315  
 Mammals, 18, 67, 68, 74, 124  
 Marine worm, 19–21, 23  
 Marker(s), 88, 157, 162, 172, 183, 186, 189, 191, 192, 196–198, 210, 218, 225, 263, 277, 279, 281, 282, 284  
 Maternal supplementation, 171  
 Mathematical model, 40, 53, 54, 310, 321  
 Mathematical modelling, 1, 27, 33, 39, 49–51, 54, 55, 322  
 McArdle's disease, 183, 185, 188, 197–199  
 M-CK, 53, 124–126, 129–135, 138–140, 312, 318  
 MCT1, 85  
*Mdx*, 8, 183, 186, 187  
 Meat, 6, 7, 150, 207, 245, 264, 318  
 Meat extract, 6, 291, 292  
 Mechanoreceptor cell, 315  
 MELAS, 185, 195, 196, 198, 199, 221, 222  
 Melatonin, 227  
 Membrane potential, 54, 67, 206, 225, 226, 315  
 Membrane trafficking, 113  
 Membrane transport, 17, 25, 269  
 Memory, 219, 313, 323  
 Mental performance, 2, 313, 314  
 Mental retardation, 8, 68, 73, 85, 94, 99, 100, 106, 149, 152, 153, 155, 156, 159, 162, 170, 173, 222  
 Mercury, 303  
 MERRF, 221, 226  
 Meta-analysis, 193, 249  
 Metabolic acidosis, 176, 178  
 Metabolism, 1, 2, 18, 28, 30, 44, 54, 71, 108, 120, 122, 124, 126, 140, 142, 143, 149, 151, 158, 160, 162, 167, 185, 190, 205, 206, 209–211, 215, 218, 220, 222–226, 228, 246, 251, 261, 269, 310, 313–315, 319, 320, 324
- Metabolites, 11, 29, 31, 32, 40, 42, 50, 54–57, 72, 89, 119–121, 123, 124, 129–132, 134, 137, 149, 160, 170, 207, 216, 253, 263, 279, 283, 284, 321, 322, 324  
 Metabolomics, 120, 321, 323  
 Metazoan(s), 17, 18, 20, 21, 23, 24  
 Methanethiosulfonates, 104  
 Methylamine, 284, 294  
 Methylglyoxal, 316  
 Methyl group, 122, 150, 151, 161, 301, 303, 315  
 Methyl-guanidino-acetic acid, 296  
 Methylisothiourea, 292, 293, 295, 304  
 Methylisourea, 292, 293, 295, 304  
 Methylmalonate, 227  
 MgADP, 18, 41, 52  
 MgATP, 3, 18, 33, 34, 36, 41, 42, 45, 46, 52, 61  
 MHC, 194, 198  
 Michaelis-Menten, 88, 264  
 Micro-albuminuria, 281  
 Microcapillaries, 69–72, 74–77  
 Microcephaly, 155  
 Microcompartmentation, 5  
 Microglia, 91  
 Migraine, 185  
 Minocycline, 218  
 Missense mutations, 107, 153, 156, 217  
 Mitochondrial contact site, 31, 32, 317  
 Mitochondrial cytopathies, 183, 185, 188, 190, 195, 196, 198, 222  
 Mitochondrial dehydrogenases, 29, 109  
 Mitochondrial dysfunction, 159, 194, 198, 205, 206, 208, 209, 211, 215, 218, 220, 221, 225–227  
 Mitochondrial encephalopathies, 159, 185, 221, 222  
 Mitochondrial myopathy, 111, 185, 187, 196  
 Mitochondrial permeability transition, 160, 212, 225  
 Mitochondrial permeability transition pore, 8, 9, 44, 208, 211  
 Mitochondrial respiration, 4, 10, 27, 44, 45, 50–53, 207, 218, 316  
 Mitochondriopathy, 155  
 M-line, 4, 51, 134  
 MNGIE, 221  
 Model, 2, 7–9, 30, 40, 43, 44, 49, 51, 53–55, 85, 88, 95, 99, 103–106, 110–113, 119, 120, 125, 140, 142, 143, 160–162, 183, 186, 205, 211–213, 215, 217, 218, 220, 223, 225–228, 252, 254, 262, 267, 269, 276, 277, 310, 313, 316, 319–323, 325  
 Modeling, 1, 2, 27, 33, 39, 49–51, 53–57, 310, 322

- Molecular mass(es), 102, 103, 109, 296  
 Monocarboxylate transporter, 1 85  
 Monocarboxylate transporter, 94  
 Monocyte(s), 100  
 Mood, 314  
 Morbidity, 189  
 Mortality, 71, 126, 189  
 Motor and sensory neuropathies, 184  
 Motor neuron disease, 218  
 Motor performance, 213, 218  
 Mouse, 2, 5, 7, 8, 52, 68, 69, 71, 74, 76, 77, 88,  
     90, 91, 94, 99, 100, 102, 109, 112, 120–123,  
     125–128, 130–132, 135, 139, 142, 143,  
     160–162, 188, 212–214, 218, 253–255, 310,  
     313, 322, 323, 326  
 M-protein, 5  
 MPTP, 215, 216  
 MRI, 153, 171, 173, 195  
 mRNA, 11, 69–72, 74, 86, 89, 90, 92, 108, 150,  
     198, 250, 255, 314, 321  
 MRS, 119–123, 125–135, 137–144, 149, 152,  
     154, 156–158, 168, 171, 172, 174, 176, 192,  
     196, 210, 214, 324  
 mtCK, 4–6, 9, 21, 23, 27, 28, 30–34, 36, 37,  
     39–45, 54, 55, 57, 58, 316, 317,  
 mTOR, 112  
 MR visible molecules, 121  
 MTS, 104, 105  
 MTSEA, 104, 105  
 Müller cell(s), 83, 84, 92, 93  
 Müller glia, 73, 92, 93  
 Multi-cellular animal, 17, 21, 23, 25  
 Multi-centre studies, 323, 324  
 Multienzyme complex, 9  
 Multifocal spikes, 152  
 Muscle aging, 135  
 Muscle anabolism, 248  
 Muscle CK (M-CK), 134  
 Muscle contraction, 3, 4, 99, 112, 247, 248, 253  
 Muscle cramping, 185, 275–277  
 Muscle damage, 276–278  
 Muscle disease, 267  
 Muscle fiber, 6, 49, 51, 121, 193–195, 223, 250,  
     251, 254, 256  
 Muscle fiber-type, 254  
 Muscle growth, 7, 246, 249, 250  
 Muscle relaxation, 8, 9, 187, 247, 249  
 Muscle soreness, 277, 278  
 Muscle strain, 276  
 Muscle torque, 7, 256  
 Muscle weakness, 184, 185  
 Muscular dystrophy mouse model, 8  
 Muscular hypotrophy, 155  
 Mutagenesis, 104  
 Myalgia, 193, 198  
 Myasthenia gravis, 184, 198  
 Myelination, 92, 171, 316  
 Myelin sheath, 184  
 Myoadenylate deaminase deficiency, 183,  
     188, 190  
 Myoblast(s), 111, 112, 150, 186, 251, 317  
 Myocardial infarction, 111, 276, 312  
 Myocyte, 110  
 Myofibre, 133  
 Myofibril(s), 4, 6, 28–30, 51, 52, 54, 56, 134  
*Myo*-inositol, 122, 138, 139, 171  
 Myomesin, 5  
 Myopathy, 111, 120, 159, 183–187, 189, 190,  
     195, 196, 198, 199, 270  
 Myophosphorylase deficiency, 183, 185  
 Myosin, 3, 51, 52, 193, 250  
 Myotonic (muscular) dystrophy, 183, 184,  
     191–193  
 Na<sup>+</sup>/Cl<sup>-</sup> dependent neurotransmitter  
     transporter(s), 68, 99, 100  
 N-acetyl aspartate (NAA), 121, 122, 127,  
     136–138, 171, 176, 213, 214, 227, 228  
 N-acetylglucosamine, 102  
 NARP, 195, 196  
 Natural abundance, 121, 123  
 Nausea, 281, 285  
 Necrosis, 8, 9, 44, 186, 223, 277, 278  
 Necrotic, 208, 211, 226  
 Nedd4-2, 112  
 Neocortex, 72, 161, 213  
 Neonatal mortality, 126  
 Neonatal period, 172, 174, 178, 324  
 Neonatal screening, 179, 311, 323, 324  
 Neonate, 73, 172–174, 215  
 Neostriatum, 209, 210, 215  
 Nephropathy, 195  
 Neuraxis, 68, 71  
 Neuroblastoma, 68, 70, 188  
 Neurodegeneration, 184, 205, 209, 214, 215,  
     221, 314  
 Neurodegenerative, 205, 207, 218, 227  
 Neurodegenerative diseases, 2, 8, 86, 95, 160,  
     205, 208, 209, 215, 219, 225, 313  
 Neurodevelopmental delay, 73  
 Neuroepithelium, 75  
 Neurofibrillary tangle, 220  
 Neurological, 76, 153, 154, 160, 167, 176, 214,  
     261, 269, 310, 311

- Neurological disease, 110, 113, 184, 205–207, 210, 212, 217, 228, 266, 270, 324
- Neurological symptom, 68, 73, 86, 92, 160, 162, 313
- Neurologic symptoms, 86
- Neurometabolic disorder, 2, 183–187, 189, 195, 199, 311, 313
- Neuromodulator, 10, 67, 74, 161
- Neuromuscular, 2, 8, 25, 183–186, 189, 196, 198, 199, 261, 311, 316
- Neuron(s), 10, 68–71, 73–75, 83, 85, 86, 90–94, 111, 113, 125, 136, 158, 159, 161, 184, 209, 210, 212, 215–220, 223, 226, 227, 313, 317, 319
- Neuronal death, 160, 205, 221, 223, 225
- Neuronal growth cone activity, 92
- Neuronal mitochondria, 91, 92
- Neuron–glial relationship, 92
- Neuropathology, 213
- Neuroprotection, 9, 206, 212, 214, 216, 221, 224, 225, 228, 319, 323
- Neuroprotective, 2, 9, 95, 110, 113, 162, 187, 188, 205, 208, 212, 214, 216, 218–220, 223–225, 228, 229, 311, 313, 321, 325
- Neuropsychological profile, 155, 156
- Neurostimulator, 311
- Neurotoxin, 212, 313
- Neurotransmitter, 67, 111, 161, 322
- Neurotransmitter release, 226
- Neurotransmitter:sodium symporters, 100
- Neurotransmitter transporter, 68, 99–101, 110, 111
- N-glycosidase F, 102
- Nitric oxide synthase, 216
- Nitropropionic acid, 211
- N-linked glycosylation, 102
- NMDA receptors, 160, 210, 221, 226
- NMR, 120, 213, 219, 227, 228, 250, 300–302
- Non-enzymatic conversion, 18, 19, 152, 207
- Non-invasive, 120, 121, 129, 134, 135, 143
- Non-responder, 252, 318
- Nonsense mutation, 106, 154, 170
- Non-stationary, 268
- Noradrenaline, 216
- Noradrenaline transporters, 107
- Norepinephrine (NET), 99, 100, 103
- NSS, *see* Neurotransmitter:sodium symporters
- Nucleus accumbens, 108
- Null mutation, 129, 135
- Nutritional supplement, 2
- oBRB, *see* Outer BRB
- Octamer(s), 5, 9, 21, 30–32, 212, 317
- Octameric structure, 5, 9
- Olfactory, 92
- Olfactory ensheathing glia, 91, 92
- Oligodendrocyte(s), 68–71, 73–75, 83, 91, 92, 158, 319
- Oligomer, 21
- Omnivores, 19
- Omnivorous diet, 262
- Open study, 190, 195
- Opheline, 17
- Oral dyspraxia, 155
- Organ clearance, 267
- Organism, 6, 18, 19, 21, 23–25, 261, 262, 318, 319
- Ornithine, 86, 150, 153, 169, 170, 178
- Ornithine aspartate, 178
- Ornithine hydrochloride, 175, 178
- Orotate, 305
- Orphan disease registries, 162, 324
- Osmolyte, 10, 313, 317
- Osteoblast, 314
- Osteopenia, 185, 194
- Osteoporosis, 192, 314
- Outcome variable, 183, 189, 191, 192, 278, 280
- Outer BRB, 84, 86, 90
- Outer mitochondrial membrane, 5, 9, 32, 39, 40, 45, 49, 50, 317
- $\beta$ -Oxidation defects, 188
- Oxidative phosphorylation, 9, 24, 27, 28, 32–34, 36, 37, 40, 42–45, 92, 142, 159, 216
- Oxidative stress, 5, 160, 183, 186, 187, 196, 210, 214, 226, 284
- Oxygen deprivation, 85, 141
- Pallidum, 72
- Pancreas, 67–69, 71, 72, 124, 150, 158, 207
- Paracellular movement, 262
- Paracrystalline inclusion, 188
- Parallel-tube model, 267
- Parathyroid hormone receptor, 108
- Parenchyma, 69
- Parkinson's disease, 9, 86, 95, 205, 215–217, 313, 325, 326
- Parts per million, 121, 122, 128, 171, 301, 303
- Passive diffusion, 50, 88, 321
- Pathobiochemistry, 162, 324
- Pathogenesis, 158, 162, 205, 209, 211–218, 228, 325
- Pathogenic, 106, 107, 152, 156, 170, 175, 199, 205, 207, 209, 218, 222, 310, 325

- Pathophysiological, 89, 95, 158, 160, 162, 207, 314, 324
- Pathophysiology, 2, 149, 161, 162, 169, 173, 221, 226
- Patient, 1–3, 7, 8, 68, 73, 74, 77, 83, 85, 86, 89, 92, 93, 95, 108, 112, 126, 128, 151–162, 167–176, 178, 179, 183–199, 205, 207, 210, 213–217, 219–224, 228, 252, 261, 262, 266, 267, 270, 271, 275, 278, 281, 283–286, 311–313, 315, 316, 321, 322, 324–326
- PCr, *see* Phosphocreatine
- PCr-shuttle, 4, 5, 136, 142, 208
- PDZ-domain proteins, 108
- Peptide sequences, 109
- Performance, 2, 6, 7, 134, 183, 188, 194–196, 207, 213, 218, 222, 245–252, 256, 269, 275, 279, 280, 300, 305, 311, 313, 314, 318, 326
- Perinatal mortality, 71
- Peripheral neuropathy, 184, 185
- Permeability, 8, 9, 27, 29, 39, 44, 49, 50, 74, 87, 126, 160, 208, 211, 212, 225
- Peroxynitrite, 188
- PGAA, 126–128, 132, 143
- pH, 31, 34, 54, 55, 123, 124, 129, 130, 132, 133, 135, 136, 141, 170, 263, 265, 267, 292, 294–298, 300, 304, 305
- pH regulation, 18
- Pharmacokinetics, 2, 261–263, 268, 311
- Pharmacological, 162, 314, 325
- Phenotype, 5, 6, 8, 9, 125, 126, 134, 135, 140, 153, 154, 156, 159, 161, 162, 173, 211–213, 215, 218, 221, 312, 313, 322–324
- Phorbol ester(s), 112
- Phosphagen, 17, 23
- Phosphagen kinases, 17, 23
- Phosphatidylcholine, 316
- Phosphocreatine, 1, 3–10, 17–19, 23–25, 27–29, 31–36, 40, 41, 44, 51–55, 57, 58, 67, 71, 73, 83, 85, 89, 92, 93, 99, 101, 109, 111, 122–124, 126–142, 150–152, 157, 159, 167, 172, 178, 186, 187, 187, 188, 192, 193, 195–197, 207, 208, 210, 212, 218, 220, 222–224, 227, 228, 247, 254, 266–270, 275, 276, 299, 309, 310, 312, 317, 321
- Phosphocreatinine, 18
- Phosphocyclocreatine, 141
- Phosphoenolpyruvate, 34, 46, 299
- Phosphofructokinase deficiency (GSD VII/Tarui's disease), 185, 188
- Phosphomonoesters (PME), 133, 139, 142
- Phospho-proteomics, 3
- Phosphoryl transfer, 17, 119, 129, 137
- Photoreceptor, 90
- Photoreceptor cells, 5, 32, 83–86, 92–94, 316
- Phototransduction, 86
- Phylogenetic analyses, 21, 22
- Physiological, 1, 2, 4, 5, 8, 10, 18, 21, 23, 25, 33, 46, 74, 88, 89, 95, 99, 100, 119, 132, 143, 144, 158, 160, 162, 169, 171, 252, 253, 297, 305, 309, 310, 312, 321, 322, 325, 327
- Placebo, 7, 189, 191–194, 196, 197, 214, 217, 219, 248–250, 277, 278, 284–286
- Plants, 100
- Plasma, 73, 85–88, 102, 149, 157, 160, 170, 172, 174–176, 178, 222, 264–266, 269, 271, 277, 278, 280, 281, 315, 316
- Plasma membrane, 4, 18, 19, 30, 86, 95, 99, 100, 109–113, 266, 269, 271
- Plasticity, 6, 143
- Pleiotropic effects, 1, 3, 7, 8, 10, 11, 322, 326
- Pleiotropy, 309, 312, 318
- Polar cells, 5, 84
- Polyacrylamide gels, 102, 109
- Polyglutamine, 209, 211
- Polymorphism, 107, 108, 318
- Polymyositis, 185, 189, 195, 318
- Polyneuropathy, 184
- Pompe's disease, 185
- Pons nuclei, 70, 72
- Porin, 5, 9, 30, 31
- Postnatal, 69, 76, 133, 178
- Powder(s), 246, 264
- Ppm, *see* Parts per million
- Prednisolone, 187, 194
- Prednisone, 185, 190, 191, 195
- Pre-symptomatic, 73, 163, 178, 179
- Pre-symptomatic treatment, 73, 159, 167, 170, 173
- Primordium, 71
- Privileged access, 36
- Properties, 30, 40, 44, 92, 100–102, 143, 160, 227, 291, 295, 304, 305, 317, 321
- Prophylactic Cr administration, 9
- Prophylaxis, 321
- Prostaglandin E<sub>2</sub>, 277, 278
- Protein carbonylation, 227
- Protein degradation, 186
- Protein kinase C, 112
- Protein nitration, 210
- Protein-protein interaction, 323
- Protein restriction, 153, 169
- Protein supplementation, 252
- Protein synthesis inhibitors, 112
- Proteolipid, 28, 30–32
- Proteomics, 3, 315, 321, 323
- Protochordate(s), 18, 19, 21, 23

- Proton buffer, 18  
 Proton buffering, 17, 129  
 Protostome, 20, 21  
 Pruritus, 285  
 Psychomotor development, 172, 176, 178, 316  
 Pufferfish, 101  
 Purification, 102, 295, 304  
 Purity, 2, 295, 303  
 Purkinje, 108  
 Pyramidal cell layer, 108  
 Pyruvate, 246, 299, 304  
 Pyruvate kinase, 34, 46
- Quality, 189, 284, 291, 303, 304, 311, 318  
 Quality of life, 189  
 Quality standard, 291, 304, 311  
 Quaternary structure, 21, 23
- R6/2 HD, 212, 213, 228  
 Radiofrequency field, 121  
 Radiofrequency probe, 140, 144  
 Randomized, 183, 190–198, 216, 217, 219, 222  
 Rapamycin, 112  
 Raptors, 19  
 Rash, 285  
 Rate-determining, 268  
 Ratio, 8, 9, 33, 34, 40, 52, 54, 75, 76, 87, 88, 100, 101, 106, 124, 125, 129–132, 134, 136, 137, 149, 154–157, 162, 174, 176, 192, 210, 220, 223, 228, 276, 279, 280, 285, 301, 317  
 Reabsorption, 102, 157, 267, 268  
 Reaction rate, 34  
 Reactive oxygen species, 8–10, 44, 112, 186, 188, 206, 208, 220, 225, 227, 253, 297, 317  
 Receptor, 10, 31, 77, 108, 160, 161, 226, 227  
 $\beta$ -Receptor agonist, 111  
 Recommended dose, 286  
 Recovery intervals, 247  
 Redox potential, 211  
 Redundancy, 143, 319, 323  
 Reflux, 285  
 Regimens, 86, 128, 207, 215, 246, 261, 262, 270  
 Regulation, 18, 27, 45, 46, 48–51, 53, 99, 109–113, 134, 150, 162, 188, 199, 206, 213, 251, 266, 270, 305, 315, 317, 318, 320, 321, 325  
 Regulatory status, 2, 305, 311  
 Rehabilitation, 2, 245–247, 250–252, 256, 311  
 Renal dysfunction, 275, 279, 281, 282, 286  
 Renal failure, 194  
 Renal function, 195, 246, 271, 279, 281–283  
 Repair, 135, 206, 313, 314
- Residues, 31, 40, 103–108, 112, 170  
 Resistance training, 245, 248–250, 252  
 Resonance frequencies, 121, 123  
 Respiratory insufficiency, 188  
 Retina, 2, 5, 32, 69, 71, 73, 83–95, 99, 108, 109, 136, 314, 321  
 Rhabdomyolysis, 277, 278  
 Rheumatologic, 194  
 Riluzole, 217  
 Risk (increased), 217, 227, 284  
 RNA interference, 319  
 Rod cell, 84  
 Rofecoxib, 216  
 ROS, *see* Reactive oxygen species  
 RT-PCR, 89, 92
- S*-adenosyl-L-methionine:guanidinoacetate  
*N*-methyltransferase, 85, 94, 150, 151  
 Safety, 2, 214, 219, 228, 246, 275, 276, 283, 284, 311  
 Sarcolemma, 28, 29  
 Sarcolemmal membrane, 52, 109  
 Sarcomere, 29, 51  
 Sarcomeric M-band, 4, 5  
 Sarcomeric mitochondrial CK, 124–126, 129–131, 133, 134, 139, 140  
 Sarcoplasmic reticulum, 4, 8, 9, 28–30, 52–54, 134, 247  
 Sarcosinate, 292–295, 304  
 Sarcosine, 284, 292–296  
 Satellite cell, 133, 135, 245, 249  
 Saturation transfer, 126, 127, 132–134, 137, 142  
 SCAM, *see* Substituted cysteine accessibility method  
 ScCKmit, *see* Sarcomeric mitochondrial CK  
 Screening, 149, 156, 179, 198, 199, 311, 323, 324  
 Sea squirt, 19  
 Sea urchin, 19–21  
 Seawater, 19  
 Secondary inflammation, 186  
 Secondary mitochondrialriopathy, 155  
 Secretion, 267, 317  
 Seizure, 135, 136, 153, 155, 160, 169, 170, 178, 185, 222, 226–228  
 Semantic-pragmatic language disorder, 155  
 Sensorimotor function, 135  
 Sensory, 5, 95, 136, 184, 219, 224, 315  
 Sepsis, 112, 316  
 Sequelae, 21, 73, 154, 167, 225, 310, 316  
 Sequence alignment, 20  
 Sequencing microarray, 324  
 Serotonin, 100, 107

- Serotonin transporter, 105  
Serum, 34, 88, 102, 112, 125, 170–173, 191, 192, 194, 214, 215, 277–279, 281, 282, 299, 318  
Serum and glucocorticoid inducible kinase, 112  
SGK1, 112  
SGK3, 112  
Short-term, 194, 198, 199, 222, 246–249, 275  
Shuttle, 4–6, 83, 85, 92, 93, 125, 134–136, 142, 208  
Side effect(s), 2, 7, 172, 185, 186, 191, 194, 195, 197, 246, 265, 275, 284, 286, 323, 326  
Signaling network, 1, 10  
Signaling pathways, 112, 250  
Signal transduction, 32, 150  
Single-blinded study, 190  
Single dose, 248, 262, 268  
Site-directed mutagenesis, 104  
Skeletal muscle, 4, 33, 40, 45, 99, 108–112, 123, 125–130, 132–136, 137–141, 143, 150, 157, 184–186, 188, 198, 199, 207, 222, 223, 245, 247, 248, 251, 253, 261, 262, 265–268, 270, 271, 275, 276, 318  
Skin, 9, 109, 280, 285, 314, 315  
SLC6A10, 100  
SLC6A8, 83, 85, 99, 100, 106, 149–151, 165, 167, 222, 223, 310, 324, 325  
Slow-twitch (fiber), 254–256  
Smooth muscle, 28  
Social gestures, 176  
Socioeconomic, 2, 10, 11  
SOD, 217  
Sodium benzoate, 153, 169, 175  
Soleus, 111, 254, 255  
Solid dosage form, 264, 265, 283  
Solute carrier family 6 (SLC6) 99, 100, 101, 103–105, 107, 110–113, 310  
Solute transporter(s), 19  
Solution(s), 29, 31, 34, 40–44, 49, 50, 128, 144, 204, 292, 294–300, 304, 321  
Somatic growth, 172, 176  
Spatial ATP buffering, 18, 23–25  
Spatial learning, 135  
Specificity, 19, 23, 100–102, 105, 106, 108–110  
Spectroscopy, 119, 120, 149, 168, 192, 195, 208, 210, 213, 219, 220, 222, 223, 227, 228, 298, 300, 301, 324  
Speech and language delay, 8  
Spermatzoa, 5, 17, 19, 23, 24, 314  
Spin, 120, 121, 176, 301  
Spinal cord, 9, 72, 105, 224, 225, 313  
Splice error, 106, 153, 154  
Sponge(s), 21–24  
Sport(s), 2, 7, 245–247, 250, 252, 303, 311, 318, 320  
SR, *see* Sarcoplasmic reticulum  
Standardization, 319  
Startle response, 135  
Statin, 184, 185, 198, 199, 276  
Status epilepticus, 154, 226–228  
Steady-state, 195, 262, 268  
Steroid, 281, 283  
Steroid myopathy, 183, 199  
Striated muscle, 85, 320  
Striatum, 72, 108, 213, 215, 313, 315  
Stroke, 185, 186, 188, 198, 205, 206, 221, 223–226  
*Strongylocentrotus*, 19–21  
Structure, 2, 5, 9, 11, 21, 23, 28–31, 43, 49, 69–72, 78, 84, 99, 102–104, 107, 133, 156, 267, 292, 296, 303, 310, 315  
Structure–function relationship, 28  
Substantia nigra, 215, 216  
Substituted cysteine accessibility method, 104, 105  
Substrate binding site, 103–107  
Substrate deprivation, 169, 178  
Substrates, 2, 3, 17, 22, 28, 30, 32–34, 36, 39, 43, 45, 74, 101, 103–107, 111, 119, 129, 140, 141, 155, 160, 169, 170, 175, 178, 221, 251, 266, 312, 321, 322  
Substrate specificity, 101, 105, 106  
Subventricular zone, 76  
Sucrose, 34, 87  
Sugars, 265  
Sulphydryl-modifying reagents, 104  
Superfamily, 21  
Superior olivary complex, 315  
Superoxide, 208  
Superoxide dismutase, 217, 227  
Supplementation, 2, 3, 6–11, 68, 69, 73, 83, 86, 93, 95, 110, 111, 113, 122, 127, 128, 132, 150, 152–155, 157, 158, 167–172, 175, 178, 183, 185–189, 191–199, 205–208, 212, 214–216, 218–225, 228, 245–256, 261, 266–271, 275–284, 286, 303, 311, 313–316, 318–321, 325–327  
Supraphysiologic doses, 261, 263, 270, 275, 279  
Surrogate marker(s), 183, 189, 198, 263  
Suspension(s), 86, 264  
Sweated beef, 7  
Synapse, 111  
Synaptic density, 159  
Synaptogenesis, 74  
Synergistic effect, 160, 305  
Syntaxin 1A, 107

- Systemic circulation, 267, 270  
Systems biology, 1, 3, 10, 309, 319, 321, 322
- Tablet, 264, 305  
Tachyarrhythmia, 317  
Tandem mass spectrometry, 173, 174, 324  
Target tissues, 261, 265, 270  
Tartrate, 304  
Tarui's disease (phosphofructokinase deficiency/GSD VII), 185  
Tau (taurine), 34, 100, 121, 122, 138, 139, 317  
Taurocyamine, 17  
tBLASTn, 20  
Telencephalon, 69, 70  
Telopeptide, 191, 192, 314  
Temporal ATP buffering, 25  
Terminals, 92, 215  
Testes, 207, 265  
Testis, 100  
Tetanic stimulation, 134  
Thalamus, 208, 221, 226  
Thalassemine, 17  
Therapeutic, 173, 183, 184, 187–190, 198, 199, 207, 212, 213, 215–219, 221, 222, 227, 228, 245, 252, 261, 269, 270, 275, 276, 281, 310, 311, 322, 324  
Therapeutic strategies, 83, 94, 199, 205–207, 209, 211, 212, 221, 311  
Therapeutic target, 111, 228  
Therapy, 95, 156, 158, 162, 167–169, 172, 183, 185, 187–190, 194, 195, 198, 199, 212, 213, 217, 223, 224, 228, 251, 269, 281, 311, 314, 316, 317, 325  
Thermodynamic, 27, 30, 36, 44, 55, 310  
Thermoregulation, 135, 283, 286  
Thermoregulatory, 279, 280  
Thiourea, 304  
Threshold, 5, 53, 91, 132, 142, 216  
Tie2 promoter/enhancer, 94, 95  
Tight junction, 75, 84  
Tissue repair, 313  
TM-BBB, 88, 89  
TMs, 102–105, 107  
Topology, 104, 107  
*Torpedo marmorata*, 101, 104  
Torque, 7, 222, 247, 249, 256  
Toxicity, 73, 85, 188, 211, 219, 220, 261  
Toxicologic, 261, 276  
Trafficking, 2, 10, 74, 99, 113, 319  
Transcription factor, 211, 245, 251  
Transcription profiling, 198, 199  
Transcriptomics, 321  
Transgenic, 129, 140, 212, 213, 217, 218, 312, 315, 320  
Transgenic animals, 6, 120, 131, 132, 143, 212, 218, 320  
Transgenic mice, 9, 33, 111, 113, 119, 120, 125, 132, 134, 135, 137, 142, 143, 213, 217, 218, 312, 319  
Transgenic mouse models, 2, 7, 120, 212  
Transgenic rat, 94, 95  
Translocator, 27, 30, 150  
Transmembrane spanning domains, 102  
Transporter, 2, 8, 18, 19, 31, 32, 34, 67, 68, 74, 78, 83, 85, 88, 94, 99–105, 107, 108, 110–113, 149–152, 154, 156, 207, 213–215, 218, 222, 245, 251, 253, 255, 256, 262, 264, 266–271, 310, 312–315, 317, 318, 320–323, 325  
Trauma, 205, 224–226  
Treatment, 2, 3, 8, 46, 73, 74, 86, 89, 93, 95, 110, 128, 149, 150, 152–156, 159, 167, 169–176, 178, 179, 183, 184, 186, 188, 191–197, 211, 213, 217–224, 228, 284, 285, 297, 299, 324, 325  
Treatment strategies, 149, 150, 162, 325  
TR-iBRB, 88, 89  
Triiodothyronine, 111  
Triplet repeat disorder, 209  
TR-MUL, 92, 93  
Trophic, 75  
Tubular reabsorption, 157  
Tumor necrosis factor- $\alpha$ , 277, 278  
Tympanic function, 5  
Type I error, 199  
Type II error, 199  
Type II fibres, 186, 195  
Tyrosine phosphorylation, 112
- UbCKmit, 125, 129, 135–139, 142  
Ubiquitin ligase, 112  
Ubiquitous, 5, 6, 91, 125, 129, 161, 208, 312, 315, 323  
uCK-Mi, 91, 92  
Unclassified, 107, 108  
Up-regulate, 110, 134, 188, 199  
Urea, 173, 281, 295  
Urea cycle, 169  
Urea cycle defect, 316  
Urine, 73, 106, 125, 149, 152, 157, 169–172, 174–176, 178, 213, 222, 264, 267, 268, 271, 280, 281, 284, 291, 299  
UV detection, 300



- Vascular endothelial cells, 95  
VDAC, *see* Voltage dependent anion channel  
Vegetarian, 283  
Ventricle, 75, 143  
Ventricular dysfunction, 111  
Vertebrate(s), 18, 20, 21, 71, 109, 125, 291  
Villus, 109  
Vitamin B12 deficiency, 184  
 $V_{max}$ , 88, 89, 110, 255, 266  
VO<sub>2</sub>, 196, 280  
Voltage dependent anion channel, 5, 29–32, 49, 54  
Voltage-gated anion carrier, 5  
Vomiting, 281, 285  
Voxels, 121, 174, 176  
  
Washout, 191–193, 197, 246, 326  
Washout interval, 189  
Water influx, 246  
Weight, 6, 7, 71, 126, 131, 132, 170, 172, 176, 187, 190, 213, 218, 221, 222, 250, 281, 298, 313, 316, 326  
  
Weight loss, 208, 210, 213  
Well-being, 314, 327  
Wernicke's encephalopathy, 221  
Western blot, 89, 92  
Wheat germ agglutinin, 102  
White matter, 108, 168, 208  
Work-load, 6, 53, 56, 57, 138–140  
Worldwide, 7, 153, 154, 162, 208, 223, 225, 324  
Wrinkle, 315  
  
*Xenopus* oocytes, 101, 102, 112  
X-inactivation, 151, 156, 157  
X-linked mental retardation, 99, 100, 106, 155  
Xq28, 100  
  
Yeast, 100  
  
Zebrafish, 101, 108  
Zn<sup>2+</sup> binding sites, 107